Tavokinogene telseplasmid is under clinical development by OncoSec Medical and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tavokinogene telseplasmid’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tavokinogene telseplasmid overview

Tavokinogene telseplasmid (DNA IL-12, Interleukin-12) is under development for the treatment of metastatic melanoma and solid tumor. The drug candidate is administered through intratumoral route. The drug candidate is being developed OMS electroImmunotherapy technology that allows delivery of a DNA (nucleic acid) based cytokine coded for interleukin-12, or DNA IL-12. The therapeutic candidate targets cell-surface receptor interleukin-12. It was also under development for the treatment of solid tumors, squamous merkel cell carcinoma, mycosis fungoides, metastatic cerival cancer, cutaneous T-cell lymphoma, head and neck cancer squamous cell carcinoma and triple negative breast cancer.

OncoSec Medical overview

OncoSec Medical (OncoSec) is a biotechnology company that focusses on designing and developing gene therapies, therapeutics, and medical approaches. It offers services to stimulate body’s immune system and attack cancer. OncoSec is conducting pipeline programs for various indications which include metastatic melanoma, triple negative breast cancer and solid tumors. The company also identifies and develops novel immune-targeting agents for use with the immunogenicity platform. It conducts pre-clinical and clinical studies targeting various cancers in collaboration with various academic medical centers and companies. OncoSec is headquartered in San Diego, California, the US.

For a complete picture of Tavokinogene telseplasmid’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.